In Need of Cancer Screening or Surveillance? Don’t Let the Pandemic Stop You

Video

While the threat of COVID-19 still looms across the country, the risks of delaying cancer screenings – or active surveillance for those patients who are currently in treatment – could be greater than people think, says City of Hope’s Dr. Ravi Salgia.

While the threat of COVID-19 still looms across the country, the risks of delaying cancer screenings – or active surveillance for those patients who are currently in treatment – could be greater than people think, says City of Hope’s Dr. Ravi Salgia.

In an interview with CURE®, Salgia, who is a thoracic oncologist and the Arthur & Rosalie Kaplan Chair in medical oncology, explained how doctors are seeing a drop in screenings for things such as colon cancer and lung cancer, which is disconcerting.

“If you don't get screened, you may not be able to diagnose the early-stage disease, especially, for example, solid tumors,” Salgia said. “If you can catch it at an earlier stage, that is a chance for a cure. The later stages become more challenging.”

Salgia noted that surveillance is also being delayed, which could impact patients negatively down the line.

“Surveillance is important, because let's say if somebody was cured of their cancer, and they need to have a repeat CAT scan, but they might delay that because they don't necessarily want to be exposed,” Salgia said. “There's that fear as well.”

Ultimately, Salgia explained, regardless of the pandemic, patients and their caregivers should still be proactive about their health and continue to get screenings and surveillance as scheduled: “Do not, do not, do not delay your care. That's really the most important message I can see.”

Transcription:

I'm a medical oncologist have been doing this for over 30 years now. And we have never seen a pandemic like this in our lifetime, and this is very concerning. And what's happening for our patients is that there's a lot of trepidation in terms of screening right now. People don't want to get their screening for, let's say, colon cancer, or breast cancer, or prostate cancer, or lung cancer, and especially for lung cancer. As a thoracic medical oncologist, I take care of lung cancer patients, and we're seeing that huge drop in the screening.

It really starts with the screening, because if you don't get screened, you may not be able to diagnose the early-stage disease, especially for example, for solid tumors. If you can catch it at an earlier stage, that is a chance for a cure. The later stages become more challenging.

And the more you delay, one screening and one diagnostic testing, the more issues we will have over the future may not affect us immediately, necessarily, but it will affect us in six months, in any year and few years. That's what we're worried about. So, we really recommend for patients, if they can still get their screening done. And it's appropriate, and it's safe, that they should do it.

Then along with screening really comes to surveillance part, too. And surveillance is important, because let's say if somebody got cured of their cancer, and they need to have a repeat CAT scan, but they might delay that because they don't necessarily want to be exposed. And so, there's that fear as well.

So, screening surveillance go hand in hand. The pandemic has hurt us a lot, and especially our patients, and their caregivers, their family members, their friends, because the more you delay, the tougher the chances are for a cure and or the right therapies.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE
Related Content